For the readers interested in the stock health of Revance Therapeutics Inc. (RVNC). It is currently valued at $30.65. When the transactions were called off in the previous session, Stock hit the highs of $30.88, after setting-off with the price of $29.17. Company’s stock value dipped to $28.80 during the trading on the day. When the trading was stopped its value was $29.50.Recently in News on March 7, 2023, Revance to Participate in Upcoming Investor Conferences. Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences. You can read further details here
Revance Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $36.61 on 02/28/23, with the lowest value was $11.27 for the same time period, recorded on 06/14/22.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Revance Therapeutics Inc. (RVNC) full year performance was 100.98%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Revance Therapeutics Inc. shares are logging -16.28% during the 52-week period from high price, and 171.96% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $11.27 and $36.61.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1478788 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Revance Therapeutics Inc. (RVNC) recorded performance in the market was 66.03%, having the revenues showcasing 38.44% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.75B, as it employees total of 534 workers.
The Analysts eye on Revance Therapeutics Inc. (RVNC)
During the last month, 0 analysts gave the Revance Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 26.34, with a change in the price was noted +6.75. In a similar fashion, Revance Therapeutics Inc. posted a movement of +28.24% for the period of last 100 days, recording 1,458,734 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RVNC is recording 30.17 at the time of this writing. In addition, long term Debt to Equity ratio is set at 30.11.
Technical rundown of Revance Therapeutics Inc. (RVNC)
Raw Stochastic average of Revance Therapeutics Inc. in the period of last 50 days is set at 67.78%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 32.73%. In the last 20 days, the company’s Stochastic %K was 20.17% and its Stochastic %D was recorded 12.55%.
Considering, the past performance of Revance Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 66.03%. Additionally, trading for the stock in the period of the last six months notably improved by 13.81%, alongside a boost of 100.98% for the period of the last 12 months. The shares increased approximately by -4.16% in the 7-day charts and went up by -5.05% in the period of the last 30 days. Common stock shares were driven by 38.44% during last recorded quarter.